Evidence map›Paper›PMID 36403582›Full record

ReviewLancet (London, England)2023

Monkeypox.

Oriol Mitjà, Dimie Ogoina, Boghuma K Titanji, Cristina Galvan, Jean-Jacques Muyembe, Michael Marks, Chloe M Orkin

Erratum issued 2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Lancet (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 275 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 4 pooled it
37.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06223919 phase3active not recruitingnot on this map

Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia

TypeinterventionalSponsorUniversidad Nacional de ColombiaRan2023 to 2025Enrolled8,686ConditionsMonkeypoxArmsLC16m8
NCT07534267 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Understanding MPXV Viral Clearance in Mpox Patients and Evaluating Transmission Dynamics of MPXV and Mpox Vaccine Effectiveness in West Africa : The Republic of Guinea

Typeobservational_patient_registrySponsorLondon School of Hygiene and Tropical MedicineRan2026 to 2027Enrolled992ConditionsMpox (Monkeypox), Monkeypox
3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 4 syntheses or guidelines pooled it, 527 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  10. Article
  11. Monkeypox Virus Surveillance - United States, 2024-2025.MMWR. Morbidity and mortality weekly report · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Rethinking mpox: epidemiology, clinical variants, diagnosis, and response.Osong public health and research perspectives · 2026
    Article
  19. Article
  20. Article

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 6 countries.

Oriol MitjàSkin Neglected Tropical Diseases and Sexually Transmitted Infections section, Hospital Universitari Germans Trías i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea. Electronic address: omitja@lluita.org.
Dimie OgoinaDepartment of Internal Medicine, Infectious Diseases Unit, Niger Delta University and Niger Delta University Teaching Hospital, Bayelsa, Nigeria.
Boghuma K TitanjiDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Medecins du Cameroun (Medcamer), Yaoundé, Cameroon.
Cristina GalvanDerMalawi, Nkhotakota, Malawi.
Jean-Jacques MuyembeInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Michael MarksLondon School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, University College London Hospital, London, UK; Division of Infection and Immunology, University College London, London, UK.
Chloe M OrkinCentre for Immunobiology, Blizard Institute, Queen Mary University, London, UK.
Fundació Lluita contra les Infeccions · ESNational Institute of Biomedical Research · CDNiger Delta University · NGQueen Mary University of London · GBUniversité de Yaoundé I · CMUniversity of London · GBUniversity of Malawi · MW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainly restricted to some countries in west and central Africa. In July, 2022, WHO declared monkeypox a Public Health Emergency of International Concern, on account of the unprecedented global spread of the disease outside previously endemic countries in Africa and the need for global solidarity to address this previously neglected disease. The 2022 outbreak has been primarily associated with close intimate contact (including sexual activity) and most cases have been diagnosed among men who have sex with men, who often present with novel epidemiological and clinical characteristics. In the 2022 outbreak, the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa. Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1% and 13% require hospital admission (for treatment or isolation), and the case-fatality rate is less than 0·1%. A diagnosis can be made through the presence of Orthopoxvirus DNA in PCRs from lesion swabs or body fluids. Patients with severe manifestations and people at risk of severe disease (eg, immunosuppressed people) could benefit from antiviral treatment (eg, tecovirimat). The current strategy for post-exposure prophylaxis or pre-exposure prophylaxis for people at high risk is vaccination with the non-replicating modified vaccinia Ankara. Antiviral treatment and vaccines are not yet available in endemic countries in Africa.

Indexed as

ExanthemaMpox, MonkeypoxSexual and Gender MinoritiesVacciniaAntiviral AgentsHomosexuality, MaleHumansMalePainAntiviral Agents

Identifiers

PMID36403582
PMCPMC9671644
OpenAlexW4309513060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.